Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Etsy Inc (ETSY) vs Illumina, Inc. (ILMN) Price & Performance

Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Etsy Inc vs Illumina, Inc. — how do they compare? Etsy Inc trades at $75.11 (market cap $6.90B), while Illumina, Inc. trades at $269.34 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 5.8× Etsy Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Etsy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Illumina, Inc. for 83 Days on average.

ETSYILMN
Market Cap
$6.90B$39.95B
Volume
2,923,8673,169,503
Sector
Consumer CyclicalHealth
52-Week High
$87.03$293.69
52-Week Low
$44.05$91.00
Typical Hold Time
67 Days83 Days
Enterprise Value
$8.85B$41.31B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Etsy Inc

ETSY trades at $71.49, up 0.14% with a bearish technical signal despite recent earnings beats. The company maintains strong gross margins at 71.4% but faces declining net income margins from 10.79% in 2024 to 5.65% in 2025. Recent positive developments include AI integration initiatives and payment partnership renewals, while technical indicators show resistance near $72-$74 levels.

Wall Street maintains a bullish consensus with 53% buy ratings and $85.94 price target, representing 20% upside potential. However, negative shareholder equity and high debt levels pose significant balance sheet risks. The stock's valuation appears reasonable at 23.78 P/E, but execution on AI initiatives and margin stabilization will be critical for sustained growth.

Illumina, Inc.

Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.

Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ETSY

No sentiment data available yet.

ILMN
96% Buy4% Sell
Avg holding period · 83 Days

Top news

Latest headlines on both assets

About Etsy Inc

Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).

Read more on ETSY →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →